Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Quest Diagnostics (DGX) stock climbed slightly today, gaining just above 0% after a relatively quiet session. Investors seem to be weighing recent performance, as shares are up 17% year-to-date and ...

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

Quest Diagnostics Inc.’s DGX third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate ...

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings results.

Guardant Health, Inc. shows strong adoption and revenue growth in oncology and data. Click for my updated look at GH stock ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive ...

In just one week, Secaucus-based Quest Diagnostics announced two new product offerings: one for at-home consumer use and another for physicians. The consumer product, Genetic Insights, helps people ...